Download PDF
Thromb Haemost 2000; 83(06): 937-943
DOI: 10.1055/s-0037-1613946
Commentary
Schattauer GmbH

Heparin Induces Synthesis and Secretion of Tissue Factor Pathway Inhibitor from Endothelial Cells In Vitro

John-Bjarne Hansen
1   From the Department of Medicine, Institute of Clinical Medicine
,
Birgit Svensson
1   From the Department of Medicine, Institute of Clinical Medicine
,
Randi Olsen
2   Department of Electron Microscopy
,
Mirella Ezban
3   Novo Nordisk AS, Health Care discovery, Maalov, Denmark
,
Bjarne Østerud
4   Department of Biochemistry at the Institute of Medical Biology, University of Tromsø, Norway
,
Ruth H. Paulssen
1   From the Department of Medicine, Institute of Clinical Medicine
› Author Affiliations
Further Information

Publication History

Received 31 August 1999

Accepted after resubmission 14 February 2000

Publication Date:
14 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

TFPI is a potent inhibitor of the extrinsic coagulation system constitutively synthesized by endothelial cells. A major portion of intravascular TFPI is stored associated with endothelial cells, and administration of unfractionated heparin (UFH) in vivo causes a prompt mobilization of TFPI into the circulation. The present study was conducted to investigate how UFH affected the synthesis, secretion and anticoagulant potency of TFPI in endothelial cells in vitro. A spontaneously transformed immortal endothelial cell line was used (ECV304). Stimulation of ECV304 cells with UFH caused a prompt dose-dependent (0-5 IU UFH/ml) release of TFPI to the medium accompanied by no change of TFPI at the surface membrane assessed by immunocytochemical methods. Northern blot analysis revealed two mRNA transcripts for TFPI with a molecular size of 1.4 kb and 4.4 kb, respectively. Stimulation of ECV304 cells for 24 hrs with various concentrations of UFH caused a dose-dependent increase of TFPI in the medium (6.2-29.6 ng/106 cells within the concentration range 0-10 IU/ml). A similar dose-dependent increase in the expression of both TFPI mRNA species was observed. Long-term incubation of ECV304 cells with 5.0 IU/ml UFH caused a 5-10 fold increase in the TFPI concentration accumulated in the medium over 48 hrs. The increased TFPI mRNA expression induced by UFH appeared already after 10 min, peaked after 2-4 hrs, remained augmented throughout the entire period of UFH exposure, and preceeded the synthesis-dependent increase in TFPI release by 2-4 hrs. The procoagulant activity of the cells was downregulated by 36 % and the contribution of TFPI to the anticoagulant potency of ECV304 cells was moderately increased after 24 hrs heparin stimulation. It is suggested that these mechanisms are of major importance for the anticoagulant function of heparins.

Keywords

Endothelial cells - heparin - TFPI - anticoagulant function
 

  • References

  • 1 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
    CrossrefPubMedGoogle Scholar
  • 2 Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a “prima ballerina”. Thromb Haemostas 1995; 74: 7-17.
    PubMedGoogle Scholar
  • 3 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43.
    PubMedGoogle Scholar
  • 4 Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemostas 1988; 60: 453-6.
    PubMedGoogle Scholar
  • 5 Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. 1988; Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 263: 6001-4.
    PubMedGoogle Scholar
  • 6 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze Jr GJ. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
    CrossrefPubMedGoogle Scholar
  • 7 Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995; 118: 178-82.
    CrossrefPubMedGoogle Scholar
  • 8 Petersen JGL, Meyn G, Rasmussen JS, Christiansen L, Petersen J, Bjørn SE, Jonassen I, Nordfang O. Characterization of human tissue factor pathway inhibitor (TFPI) variants expressed in saccharomyces cerevisae. J Biol Chem 1993; 268: 13344-51.
    PubMedGoogle Scholar
  • 9 Wesselschmidt R, Likert K, Huang Z, Broze Jr GJ. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 04: 661-9.
    CrossrefPubMedGoogle Scholar
  • 10 Nordfang O, Bjørn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant actvity. Biochemistry 1991; 30: 10371-6.
    CrossrefPubMedGoogle Scholar
  • 11 Wesselschmidt R, Likert KM, Girard TJ, Wun TC, Broze Jr GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-10.
    PubMedGoogle Scholar
  • 12 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj P. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
    CrossrefPubMedGoogle Scholar
  • 13 Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human umbilical cells in culture. Arterioscler Thromb Vasc Biol 1995; 15: 2055-62.
    CrossrefPubMedGoogle Scholar
  • 14 Hansen JB, Olsen R, Webster P. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood 1997; 90: 3568-78.
    PubMedGoogle Scholar
  • 15 Warn-Cramer BJ, Almus FE, Rapaport SI. Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Haemostas 1989; 61: 101-5.
    PubMedGoogle Scholar
  • 16 Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992; 79: 3219-26.
    PubMedGoogle Scholar
  • 17 Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor dependent blood coagulation. Thromb Haemostas 1991; 66: 6-15.
    PubMedGoogle Scholar
  • 18 Grabowski EF, Zuckerman DB, Nemerson Y. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 1993; 81: 3265-70.
    PubMedGoogle Scholar
  • 19 Ho G, Toomey JR, Broze Jr GJ, Schwartz AL. Receptor-mediated endocytosis of coagulation factor Xa requries cell surface-bound tissue factor pathway inhibitor. J Biol Chem 1996; 271: 9497-502.
    CrossrefPubMedGoogle Scholar
  • 20 Sevinsky JR, Rao LVM, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133: 293-304.
    CrossrefPubMedGoogle Scholar
  • 21 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
    CrossrefPubMedGoogle Scholar
  • 22 Novotny WF, Palmier M, Wun TC, Broze Jr. GJ, Miletich JP. Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400.
    PubMedGoogle Scholar
  • 23 Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinzed blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-68.
    CrossrefPubMedGoogle Scholar
  • 24 Valentin S, Østergaard P, Kristensen H, Norfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coagul Fibrinolysis 1992; 03: 221-2.
    CrossrefPubMedGoogle Scholar
  • 25 Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Hansen JB, Sandset PM, Huseby KR, Huseby NE, Bendz B, Østergaard P, Nordøy A. Differential effect of unfractionated and low molecular weight heparin on intravascular tissue factor pathway inhibitor (TFPI): evidence for a difference in antithrombotic action. Br J Haematol 1998; 101: 638-46.
    CrossrefPubMedGoogle Scholar
  • 27 Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327: 141-5.
    CrossrefPubMedGoogle Scholar
  • 28 Hansen JB, Sandset PM. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor: a possible mechanism for difference in therapeutic efficacy. Thromb Res 1998; 91: 177-81.
    CrossrefPubMedGoogle Scholar
  • 29 Erhardsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 05: 388-95.
    PubMedGoogle Scholar
  • 30 Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 09 (Suppl. 027) 1-173.
    CrossrefPubMedGoogle Scholar
  • 31 Nesheim ME, Myrmel KH, Hibbard L, Mann KG. Isolation and characterization of single chain bovine factor V. J Biol Chem 1979; 254: 508-17.
    PubMedGoogle Scholar
  • 32 Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purification of prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412.
    PubMedGoogle Scholar
  • 33 Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens 1997; 50: 449-58.
    CrossrefPubMedGoogle Scholar
  • 34 Johansen T, Bjørkøy G, Øvervatn A, Diaz-Meco MT, Traavik T, Moscat J. NIH 3Ts cells stably transfected with the gene encoding phosphatidylcholine-hydrolyzing phospholipase C from Bacillus cereus acquire a transformed phenotype. Mol Cell Biol 1994; 14: 646-54.
    CrossrefPubMedGoogle Scholar
  • 35 Cleveland DW, Lopata MA, MacDonald RJ, Cowan NJ, Rutter WJ, Kirschner MW. Number and evolutionary conservation of alpha-and betatubulin and cytoplasmic beta-and gammaactin genes using specific cloned cDNA probes. Cell Signal 1980; 20: 95-105.
    PubMedGoogle Scholar
  • 36 Maniatis T, Frisch EF, Sambrook J. Molecular cloning. A laboratory manual. Cold Spring Harbor laboratory, Cold Spring Harbor; 1982
    Google Scholar
  • 37 Paulssen EJ, Paulssen RH, Haugen TB, Gautvik KM, Gordeladze JO. Cell-specific distribution of guanine nucleotide-binding regulatory proteins in rat pituitary tumour cell lines. Mol Cell Endocrinol 1991; 76: 45-53.
    CrossrefPubMedGoogle Scholar
  • 38 Liou W, Gueze HJ, Slot JW. Improving structural integrity of cryosections for immunogold labeling. Histochem Cell Biol 1996; 106: 41-58.
    CrossrefPubMedGoogle Scholar
  • 39 Mayhew TM, Gundersen HJ. If you assume, you can make an ass out of u and me: a decade of the sisector for stereological counting of particles in 3D space. J Anat 1996; 188: 1-15.
    PubMedGoogle Scholar
  • 40 Lucocq J. Quantitation of gold labelling and antigens in immunolabelled ultrathin sections. J Anat 1994; 184: 1-13.
    PubMedGoogle Scholar
  • 41 Østerud B. Platelet activating factor enhancement of lipopolysaccharideinduced tissue factor activity in monocytes: requirement of platelets and granulocytes. J Leuk Biol 1992; 51: 462-5.
    CrossrefPubMedGoogle Scholar
  • 42 SAS. SAS/STAT Guide for personal computers, version 6. SAS Institute, Cary NC; 1987
    Google Scholar
  • 43 Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
    CrossrefPubMedGoogle Scholar
  • 44 Valentin S, Larnkjær A, Østergaard P, Nielsen JI, Nordfang O. Characterization of the binding beteen tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-83.
    CrossrefPubMedGoogle Scholar
  • 45 Iversen N, Sandset PM, Abildgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to cultured endothelial cells influence of glycosaminoglycans. Thromb Res 1996; 84: 267-78.
    CrossrefPubMedGoogle Scholar
  • 46 Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus for tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 1993; 04: 713-20.
    CrossrefPubMedGoogle Scholar
  • 47 Tieman C, Brinkmann T, Kleesiek K. Detection of the three kunitz-type single domains of membrane-bound tissue factor pathway inhibitor (TFPI) by flow cytometry. Eur J Clin Chem Biochem 1997; 35: 855-60.
    PubMedGoogle Scholar
  • 48 Lupu C, Kanthou C, Lupu F, Kakkar VV. Heparin induces release of intracellular tissue factor pathway inhibitor from human endothelial cells in culture. Thromb Haemost. 1997 suppl: 565. (abstract).
    PubMedGoogle Scholar
  • 49 Almus FE, Rao LVM, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993; 13: 105-11.
    CrossrefPubMedGoogle Scholar
  • 50 Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiological role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-712.
    CrossrefPubMedGoogle Scholar
  • 51 Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53: 231-41.
    CrossrefPubMedGoogle Scholar